Literature DB >> 3139426

Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease.

M A Barradas1, D S Gill, V A Fonseca, D P Mikhailidis, P Dandona.   

Abstract

Intraplatelet serotonin (5-HT) content was determined in 23 patients with type I (insulin-dependent) diabetes mellitus (IDDM), 23 patients with type II (non-insulin-dependent) diabetes mellitus (NIDDM), 29 patients with peripheral vascular disease (PVD) and 34 age-matched normal subjects. Intraplatelet 5-HT content in normal subjects showed an age-related decline (r = -0.45; P less than 0.008), as has been previously demonstrated. The median 5-HT content in platelets of the young normal subjects was 4.36 (range: 3.62-6.79) nmol 10(-9) platelets, while that in the elderly normal subjects was 3.87 (range: 2.8-6.0) nmol 10(-9) platelets and that in young + elderly subjects was 4.05 (range: 2.8-6.8) nmol 10(-9) platelets. The median intraplatelet 5-HT content was significantly lower (P less than 0.002) in IDDM patients: 3.0 (range 1.3-6.3), NIDDM patients: 2.5 (range 1.7-5.8), PVD patients: 2.42 (range 0.94-4.98) nmol 10(-9) platelets than that in all young + elderly healthy subjects. The presence of hypertension in DM patients caused a small but significant (P less than 0.05) decrease in intraplatelet 5-HT content, whilst its presence had no effect in PVD patients. In a smaller study, it was established that NIDDM and PVD patients have significantly (P less than 0.002) greater plasma 5-HT concentrations than controls. Insulin-dependent diabetes mellitus patients had greater plasma 5-HT concentrations but this did not achieve statistical significance despite a 66% increment in its value.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139426     DOI: 10.1111/j.1365-2362.1988.tb01030.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  22 in total

1.  Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress.

Authors:  Christopher B Pattillo; Shyamal C Bir; Billy G Branch; Eric Greber; Xinggui Shen; Sibile Pardue; Rakesh P Patel; Christopher G Kevil
Journal:  Free Radic Biol Med       Date:  2010-11-09       Impact factor: 7.376

2.  Inhibitory effect of 5-hydroxytryptamine on penile erectile function in the rat.

Authors:  J P Finberg; Y Vardi
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

3.  Low serum cholesterol and serotonin metabolism. Results may have been affected by confounding.

Authors:  H Pijl; A C Toornvliet; A E Meinders; J A Leuven; C M Van Kempen
Journal:  BMJ       Date:  1996-05-18

Review 4.  Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

5.  GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake.

Authors:  Yicong Li; Coedy Hadden; Preeti Singh; Charles P Mercado; Pamela Murphy; Nafisa K Dajani; Curtis L Lowery; Drucilla J Roberts; Luc Maroteaux; Fusun Kilic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

6.  Molecular interactions of serotonin (5-HT) and endothelin-1 in vascular smooth muscle cells: in vitro and ex vivo analyses.

Authors:  Subha Bhaskaran; Jeremy Zaluski; Amy Banes-Berceli
Journal:  Am J Physiol Cell Physiol       Date:  2013-11-06       Impact factor: 4.249

7.  Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.

Authors:  Shinya Kobayashi; Minoru Satoh; Tamehachi Namikoshi; Yoshisuke Haruna; Sohachi Fujimoto; Sayaka Arakawa; Norio Komai; Naruya Tomita; Tamaki Sasaki; Naoki Kashihara
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

8.  Risk factors for coronary artery sclerosis in patients with diabetes.

Authors:  Akihiro Nishiyama; Chihiro Shikata; Nobuaki Kimura; Akio Imanishi; Noriyuki Hirai; Makoto Ohta; Nobuakira Takeda
Journal:  Exp Clin Cardiol       Date:  2005

9.  Effects of the 5-HT2A Antagonist Sarpogrelate on Walking Ability in Patients with Intermittent Claudication as Measured Using the Walking Impairment Questionnaire.

Authors:  Hiroshi Matsuo; Hiroshi Shigematsu
Journal:  Ann Vasc Dis       Date:  2008-09-25

10.  Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study.

Authors:  Refik Demirtunc; Dursun Duman; Melih Basar
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.